Inflammation-induced promoter hypermethylation of GLP-1R limits the protective effect of GLP-1R agonists against acute lung injury.
Summary
Inflammation upregulates DNMT3A/3B to hypermethylate the GLP-1R promoter, silencing GLP-1R and blunting GLP-1RA efficacy in ALI. Restoring GLP-1R expression via lentiviral or AAV approaches re-sensitized tissues and outperformed GLP-1RA monotherapy in vivo.
Key Findings
- LPS reduced GLP-1R expression in endothelial, bronchial epithelial, and alveolar epithelial cells and in ALI mouse lungs.
- DNMT3A/3B upregulation induced GLP-1R promoter hypermethylation, reduced chromatin accessibility, and transcriptional silencing.
- Restoring GLP-1R (lentivirus/AAV) reinstated GLP-1RA anti-inflammatory effects and improved in vivo protection vs GLP-1RA alone.
Clinical Implications
GLP-1RAs may require companion strategies to restore GLP-1R expression (e.g., epigenetic modulators or gene therapy) and careful patient selection; monotherapy could fail in hyperinflammatory states.
Why It Matters
Reveals an epigenetic mechanism of drug resistance and demonstrates a concrete re-sensitization strategy with in vivo efficacy, reshaping how GLP-1RAs might be deployed for ALI/ARDS.
Limitations
- Preclinical models; absence of human interventional validation
- Predominantly LPS-induced ALI; generalizability to heterogeneous ARDS etiologies uncertain
Future Directions
Validate GLP-1R methylation status in human ARDS, develop epigenetic or gene-based GLP-1R restoration strategies, and design stratified clinical trials of GLP-1RAs with companion diagnostics.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical experimental study in animals and cell lines
- Study Design
- OTHER